Skip to main content

Advertisement

SpringerLink
Log in

Curcumin reverses cisplatin resistance in cisplatin-resistant lung caner cells by inhibiting FA/BRCA pathway

  • Research Article
  • Published:
Tumor Biology

Abstract

Cisplatin (DDP) is the most widely used chemotherapy agent for treatment of malignancies including lung cancer. However, the effectiveness of DDP is often weakened by acquired resistance of tumor cells. DDP kills cancer cells primarily by creating intrastrand and interstrand DNA cross-links, which block DNA replication. The Fanconi anemia (FA)/BRCA pathway is a DNA cross-link damage repair pathway, which regulates cellular resistance to DNA cross-link agents, such as DDP. Some study has shown that natural compound curcumin sensitize human ovarian and breast cancer cells to DDP. However, whether curcumin may reverse resistance to DDP in DDP-resistant lung cancer cells has not been understood. In this study, we showed that curcumin enhanced the proliferation inhibitory effect of DDP and promote DDP-induced apoptosis in A549/DDP cells (DDP-resistant lung adenocarcinoma cells). Moreover, we observed that FA/BRCA pathway DNA damage repair processes, such as DDP-induced FANCD2 monoubiquitination and nuclear foci formation were downregulated in the presence of curcumin, suggesting that curcumin enhanced sensitivity to DDP in A549/DDP cells through the inhibition of FA/BRCA pathway. Furthermore, the calculation of q value and apoptosis analyses revealed that curcumin in combination with DDP could exert a synergistic cytotoxic effect in A549/DDP cells, further demonstrating that curcumin can reverse cisplatin resistance of A549/DDP cells. In conclusion, by suppressing the FA/BRCA pathway DNA repair, curcumin potentiates DDP-induced proliferation inhibitory effect and apoptosis in A549/DDP cell, indicating that curcumin may serve as a chemosensitizer to cross-link-inducing anticancer drugs DDP.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Spira SG, Silvestri GA. The treatment of advanced non-small cell lung cancer. Curr Opin Pulm Med. 2005;11:287–91.

    Article  Google Scholar 

  2. Massarelli E, Herbst RS. Use of novel second-line target therapies in non-small cell lung cancer. Semin Oncol. 2006;33 suppl 1:s9–16.

    Article  CAS  PubMed  Google Scholar 

  3. Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med. 2004;350:379–92.

    Article  CAS  PubMed  Google Scholar 

  4. Resell R, Cecere F, Santarpia M, Noemi R, Miquel T. Predicting the outcome of chemotherapy for lung cancer. Curr Opin Pharmacol. 2006;6:323–31.

    Article  Google Scholar 

  5. Kartalou M, Essigmann JM. Mechanisms of resistance to cisplatin. Mutat Res. 2001;478:23–43.

    Article  CAS  PubMed  Google Scholar 

  6. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 2007;7:573–84.

    Article  CAS  PubMed  Google Scholar 

  7. Kennedy RD, D’Andrea AD. DNA repair pathway in clinical practice: lesions from pediatric cancer susceptibility syndromes. J Clin Oncol. 2006;24:3799–808.

    Article  CAS  PubMed  Google Scholar 

  8. Kim H, D’Andrea AD. Regulation of DNA Cross-link repair by the Fanconi anemia/BRCA pathway. Genes Dev. 2012;26:1393–408.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Auerbach AD. Fanconi anemia and its diagnosis. Mutat Res. 2009;668:4–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Alan D. The Fanconi anemia and breast susceptibility pathway. N Engl J Med. 2010;362:1909–19.

    Article  PubMed Central  Google Scholar 

  11. Kee Y, D’Andrea AD. Expanded roles of the Fanconi anemia pathway in preserving genomic stability. Genes Dev. 2010;24:1680–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Su X, Huang J. The Fanconi anemia pathway and DNA interstrand cross-link repair. Protein Cell. 2011;2:704–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Taniguchi T, Tischkowitz M, Ameziane N, Hodgson SV, Mathew CG, Joenje H, et al. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med. 2003;9:568–74.

    Article  CAS  PubMed  Google Scholar 

  14. Sakai W, Swisher EM, Karlan BY, Agarwal MK, Higgins J, Friedman C, et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA-mutated cancers. Nature. 2008;451:1116–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Jagtap S, Meganathan K, Wagh V, Winkler J, Hescheler J, Sachinidis A. Chemoprotective mechanism of the natural compounds, epigallocatechin-3-O-gallate, quercetin and curcumin against cancer and cardiovascular diseases. Curr Med Chem. 2009;16:1451–62.

    Article  CAS  PubMed  Google Scholar 

  16. Shishodia S, Chalurvedi MM, Aggarwal BB. Role of curcumin in cancer therapy. Curr Probl Cancer. 2007;31:243–305.

    Article  PubMed  Google Scholar 

  17. Ye MX, Li Y, Yin H, Zhang J. Curcumin: updated molecular mechanisms and intervention targets in human lung cancer. Int J Mol Sci. 2012;13:3959–78.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Duarte VM, Han E, Veena MS, Salvado A, Suh JD, Liang LJ, et al. Curcumin enhances the effect of cisplatin in suppression of head and neck squamous cell carcinoma via inhibition of IKKβ protein of the NFκB pathway. Mol Cancer Ther. 2010;9:2665–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Xu XB, Chen B, Liu WY. Curcumin inhibits the invasion of thyroid cancer cells via down-regulation of PI3K/kt signaling pathway. Gene. 2014;546:226–32.

    Article  CAS  PubMed  Google Scholar 

  20. Zang S, Liu T, Shi J, Qiao L. Curcumin: a promising agent targeting cancer stem cells. Anticancer Agents Med Chem. 2014;14:787–92.

    Article  CAS  PubMed  Google Scholar 

  21. Chirnomas D, Taniguchi T, de la Vaga M, Vaidya AP, Vasserman M, Hartman A-R, et al. Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway. Mol Cancer Ther. 2006;5:952–61.

    Article  CAS  PubMed  Google Scholar 

  22. Xiao H, Xiao Q, Zhang K, Zuo X, Shresthan UK. Reversal of multidrug resistance by curcumin through FA/BRCA pathway in multiple myeloma cell line MOLP-2/R. Ann Hematol. 2010;89:399–404.

    Article  CAS  PubMed  Google Scholar 

  23. Shao Z-M, Shen Z-Z, Liu C-H, Sartippour MR, Heber D, Nguyen M. Curcumin exerts multiples suppressive effects on human breast carcinoma cells. Int J Cancer. 2002;98:234–40.

    Article  CAS  PubMed  Google Scholar 

  24. Chen Q, Van der Sluis PC, Boulware D, Hazlehurst LA, Dalton WS. The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells. Blood. 2005;106:698–705.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. van der Heijden MS, Brody JR, Gallemier E, Cunningham SC, Dezentje DA, Shen D, et al. Function defects in the Fanconi anemia pathway in pancreatic cancer cells. Am J Pathol. 2004;165:651–7.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Burkitt K, Ljungman M. Compromised Fanconi anemia response due to BRCA1 deficiency in cisplatin-sensitive head and neck cancer cell lines. Cancer Lett. 2007;8:131–7.

    Article  Google Scholar 

  27. Zhang J, Wang X, Lin C-J, Conch FJ, Fei P. Altered expression of FANCL confers mitomycin C sensitivity in calu-6 lung cancer cells. Cancer Biol Ther. 2006;5:1632–6.

    Article  CAS  PubMed  Google Scholar 

  28. Burkitt K, Ljurgman M. Phenylbutyrate interferes with the Fanconi anemia and BRCA pathway and sensitized head and neck cancer cells to cisplatin. Mol Cancer. 2008;7:24.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Yarde DN, Oliveira V, Mathews L, Wang X, Villagra A, Boulware D, et al. Targeting the Fanconi anemial BRCA pathway circumvents drug resistance in multiple myeloma. Cancer Res. 2009;69:9367–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Chen J, Dexheimer TS, Ai Y, Liang G, Villamil MA, Inglese J, et al. Selective and cell-active inhibitors of the USP1/UAF1 deubiquitinase complex reverse cisplatin resistance in non-small cell lung cancer cells. Chem Biol. 2011;18:1390–400.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Kee Y, Huang M, Chang S, Moreau LA, Park E, Smith PG, et al. Inhibition of the Nedd8 system sensitive cells to DNA interstrand cross-linking agents. Mol Cancer Res. 2012;10:369–77.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Litan R, Gupta R, Brosh Jr RM, Cantor SB. BRCA-FA pathway as a target for anti-tumor drugs. Anticancer Agents Med Chem. 2008;8:423–30.

    Google Scholar 

  33. Hucl T, Gallmeier E. DNA repair: exploiting the Fanconi anemia pathway as a potential therapeutic target. Physiol Res. 2011;60:453–65.

    CAS  PubMed  Google Scholar 

  34. Shukl P, Solank A, Ghos K, Vundinit BR. DNA interstrand cross-link repair: understanding role of Fanconi anemia pathway and therapeutic implications. Eur J Haematol. 2013;9:381–93.

    Article  Google Scholar 

  35. Kunnunakkara AB, Anand P, Aggarwal BB. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling protein. Cancer Lett. 2008;269:199–255.

    Article  Google Scholar 

  36. Yu LL, Wu JG, Dai HG, Si JM. Curcumin reverses chemoresistance of human gastric cancer cells by downregulating the NF-Kappa B transcritption factor. Oncol Rep. 2011;26:1197–203.

    CAS  PubMed  Google Scholar 

  37. Jana NR, Diskshit P, Goswami A, Nukina N. Inhibition of proteasomal function by curcumin induces apoptosis through mitochondrial pathway. J Biol Chem. 2004;219:11680–5.

    Article  Google Scholar 

  38. Jacquemont C, Taniguchi T. Proteasome function is required for DNA damage response and Fanconi anemia pathway activation. Cancer Res. 2007;67:7395–405.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Department of Pulmonary Medicine, Affiliated Hospital of Jiangsu University, 438 North Jiefang Street, Zhenjiang, 212001, China

    Ping Chen, Jian Li & He-Guo Jiang

  2. Institute of Medical Science, Jiangsu University, Zhenjian, China

    Ting Lan & Yong-Chang Chen

Authors
  1. Ping Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jian Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. He-Guo Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ting Lan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yong-Chang Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jian Li.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chen, P., Li, J., Jiang, HG. et al. Curcumin reverses cisplatin resistance in cisplatin-resistant lung caner cells by inhibiting FA/BRCA pathway. Tumor Biol. 36, 3591–3599 (2015). https://doi.org/10.1007/s13277-014-2996-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-014-2996-4

Keywords

Search

Navigation